Literature DB >> 17671183

p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation.

Geun-Hyoung Ha1, Kwan-Hyuck Baek, Hyun-Soo Kim, Sook-Jung Jeong, Chang-Min Kim, Frank McKeon, Chang-Woo Lee.   

Abstract

The mitotic spindle checkpoint plays a crucial role in regulating accurate chromosome segregation and preventing the adaptation of multiploid progeny cells. Recent reports have indicated that the induction of p53 by mitotic checkpoint activation is essential for protecting cells from abnormal chromosome ploidization caused by mitotic failure. However, although studies have shown that p53 deficiencies arrest mitosis, compromise apoptosis, and may cause profound aneuploidy, the molecular mechanisms leading to p53 induction following mitotic checkpoint activation remain unknown. Here, we show that the BubR1 mitotic checkpoint kinase interacts with p53 both in vitro and in vivo, with higher levels of interaction in mitotic cells. This interaction contributes to p53 phosphorylation. Silencing of BubR1 expression reduces the phosphorylation and stability of p53, whereas exogenous introduction of BubR1 proteins into BubR1-depleted cells recovers p53 stability. In addition, inhibition of BubR1 expression in the presence of a microtubule inhibitor accelerates chromosomal instability and polyploidy in p53-null cells. These results collectively suggest that p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671183     DOI: 10.1158/0008-5472.CAN-06-3392

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

Review 2.  p53: guardian of ploidy.

Authors:  Yael Aylon; Moshe Oren
Journal:  Mol Oncol       Date:  2011-07-30       Impact factor: 6.603

3.  ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1.

Authors:  G Krapf; U Kaindl; A Kilbey; G Fuka; A Inthal; R Joas; G Mann; J C Neil; O A Haas; E R Panzer-Grümayer
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

4.  Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.

Authors:  Yalcin Cirak; Yavuz Furuncuoglu; Ozlem Yapicier; Suleyman Alici; Andac Argon
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.

Authors:  Leo L Studach; Lova Rakotomalala; Wen-Horng Wang; Ronald L Hullinger; Stefano Cairo; Marie-Annick Buendia; Ourania M Andrisani
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

6.  Cross-talk between BubR1 expression and the commitment to differentiate in adipose-derived mesenchymal stem cells.

Authors:  Janet Lee; Chang Geun Lee; Kyo-Won Lee; Chang-Woo Lee
Journal:  Exp Mol Med       Date:  2009-12-31       Impact factor: 8.718

7.  TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18.

Authors:  Yi-Fu Huang; Margaret Dah-Tsyr Chang; Sheau-Yann Shieh
Journal:  Mol Cell Biol       Date:  2009-03-30       Impact factor: 4.272

8.  Unsupervised tensor decomposition-based method to extract candidate transcription factors as histone modification bookmarks in post-mitotic transcriptional reactivation.

Authors:  Y-H Taguchi; Turki Turki
Journal:  PLoS One       Date:  2021-05-25       Impact factor: 3.240

9.  Mitotic Kinases and p53 Signaling.

Authors:  Geun-Hyoung Ha; Eun-Kyoung Yim Breuer
Journal:  Biochem Res Int       Date:  2012-07-19

10.  Lower salinomycin concentration increases apoptotic detachment in high-density cancer cells.

Authors:  Ju-Hwa Kim; Tae Young Kim; Hyung Sik Kim; Suntaek Hong; Sungpil Yoon
Journal:  Int J Mol Sci       Date:  2012-10-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.